Dr. Rebecca C Shore, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Village Sq, Chelmsford, MA 01824 Phone: 978-995-3292 Fax: 978-677-7339 |
Douglas Corey Campbell, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Village Sq, Chelmsford, MA 01824 Phone: 978-995-3292 |
Dr. Abdul Ghaffar, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 35b Village Sq, Chelmsford, MA 01824 Phone: 978-256-4528 Fax: 978-256-4139 |
Dr. Roy R Shen, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Village Sq, Chelmsford, MA 01824 Phone: 978-995-3292 Fax: 978-677-7339 |
David Lee, M.D. Surgery - Plastic and Reconstructive Surgery Medicare: Not Enrolled in Medicare Practice Location: 15 Village Sq, Chelmsford, MA 01824 Phone: 978-800-1680 Fax: 978-455-4526 |
Dr. Caitlin Polistena, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Village Sqaure, Chelmsford, MA 01824 Phone: 978-995-3292 |
Janaki Varadhan, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 4 Meeting House Rd, Suite 4, Chelmsford, MA 01824 Phone: 978-256-7200 Fax: 978-258-5855 |
News Archive
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
Noroviruses are a leading cause of acute gastroenteritis (diarrhoea and vomiting) across all age groups, responsible for almost a fifth (18%) of all cases worldwide. New estimates, published in The Lancet Infectious Diseases, highlight the importance of developing norovirus vaccines, say the authors.
Allied Healthcare Group today announces it has commenced shipment of CardioCel into Europe after the Company received its first orders for the product from outside of Australia.
Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.
Chemed Corporation announced today that the Board of Directors has declared a quarterly cash dividend of 16 cents per share on the Company's capital stock, payable on March 19, 2012, to shareholders of record as of February 27, 2012.
› Verified 7 days ago